Edesa BiotechEDSA -3.23%26 EV-to-FCF is -9.46 as of Jul. 02, 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, Edesa Biotech ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Edesa Biotech's Enterprise Value is $71.18 Mil.
Edesa Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.53 Mil. Therefore, Edesa Biotech's EV-to-FCF for today is -9.46.
The historical rank and industry rank for Edesa Biotech's EV-to-FCF or its related term are showing as below:
EDSA'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.99 Med: -0.75 Max: 1.37
Current: -9.46
During the past 13 years, the highest EV-to-FCF of Edesa Biotech was 1.37. The lowest was -15.99. And the median was -0.75.
EDSA's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs EDSA: -9.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Edesa Biotech's PE Ratio (TTM) for today is calculated as:
Edesa Biotech's share price for today is $7.45.
Edesa Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Edesa Biotech EV-to-FCF Related Terms
Edesa Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Edesa Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Edesa Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edesa Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Edesa Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Edesa Biotech's EV-to-FCF falls into.
Edesa Biotech's current Enterprise Value is $71.18 Mil.
Edesa Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edesa Biotech (EDSA) has a EV-to-FCF of -9.46 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Edesa Biotech and its competitors. According to the industry distribution chart, Edesa Biotech ranks #999999 out of 333 companies in the Biotechnology industry.
Is Edesa Biotech's EV-to-FCF too high?
Edesa Biotech's current EV-to-FCF is -9.46. Based on the distribution chart, Edesa Biotech ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's EV-to-FCF compare to ACET and HRTX?
According to the Biotechnology industry distribution chart, Edesa Biotech ranks #999999 out of 333 companies for EV-to-FCF. This places Edesa Biotech in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Edesa Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edesa Biotech's current EV-to-FCF is -9.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current EV-to-FCF of -9.46. The current EV-to-FCF is -9.46. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current EV-to-FCF is -9.46 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score
Get the complete analysis for EDSA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDSA has been successfully added to your 
